Nuwellis, Inc. announced that Henry Ford Health has begun offering ultrafiltration therapy to heart failure patients suffering from fluid overload using the company's Aquadex SmartFlow system as part of Nuwellis' pivotal REVERSE-HF clinical study.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.26 USD | -1.29% | +95.49% | -55.24% |
07/05 | Top Midday Gainers | MT |
07/05 | Nuwellis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-55.24% | 4.01M | |
+8.07% | 219B | |
+7.87% | 184B | |
+12.75% | 138B | |
-1.37% | 62.54B | |
+4.88% | 52.22B | |
+11.59% | 51.73B | |
+2.71% | 41.4B | |
+4.90% | 37.17B | |
+23.75% | 31.76B |
- Stock Market
- Equities
- NUWE Stock
- News Nuwellis, Inc.
- Nuwellis, Inc. Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health